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Abstract 
BACKGROUND: Osteoarthritis (OA) is generally considered a degenerative joint disease caused by 
biomechanical changes and the ageing process. In OA pathogenesis, the development of OA is thought to be 
regulated largely by excess matrix metalloproteinase (MMP), which contributes to the degradation of extracellular 
matrices such as MMP-1 and Interleukin-4. 
AIM: This study aims to prove the influence of Mesenchymal Stem Cell Wharton Jelly on decreasing MMP-1 
levels and increasing IL-4 which is a specific target as a target component in cases of osteoarthritis in vivo. 
MATERIAL AND METHODS: This research is an experimental study with the design of Post-Test-Only Control 
Group Design. The sample consisted of 16 OA rats as a control group and 16 OA rats treated with MSC-WJ as a 
treatment group. OA induction is done by injection of monosodium iodoacetate (MIA) into the intra-articular right 
knee. Giving MSC-WJ is done in the third week after MIA induction. The serum MMP-1 and IL-4 levels were 
measured after 3 weeks treated with MSC-WJ using the ELISA method. The statistical test used is an 
independent t-test. The value of p < 0.05 was said to be statistically significant. 
RESULTS: The result showed that serum MMP-1 levels were higher in the group treated with MSC-WJ than in 
the control group (p < 0.05). Serum IL-4 levels were higher in the group treated with MSC-WJ than in the control 
group (p < 0.05). 
CONCLUSION: This study concluded that MSC-WJ increased MMP-1 levels and IL-4 levels in serum OA rats. 
MSC-WJ showed a negative effect on MMP-1 in the serum of OA rats. 
 
 
 
 
 
 
 
 
Introduction 
 
Osteoarthritis (OA) is considered a cumulative 
result of mechanical and biological events caused by 
an imbalance between catabolic and anabolic 
processes in articular joint tissue [1]. At present, the 
development of OA is thought to be regulated largely 
by excess matrix metalloproteinase (MMP), which 
contributes to the degradation of extracellular 
matrices, such as MMP-1 and MMP-3 which play an 
important role in the development of OA by 
decreasing extracellular matrix [2], where this MMP is 
induced by inflammatory mediators, such as 
interleukin-1-beta (IL-1β) and tumour necrosis factor 
alpha (TNF-α) in tissue and OA joint fluid [3]. So far 
there are no drugs available to guarantee a complete 
cure and the possibility of recurrence from OA. 
Mesenchymal stem cells (MSCs) are 
promising candidates for cartilage regeneration and 
OA therapy because they have a chondrogenic 
potential and the ability to form extracellular matrices 
[4]. Also, MSC has an immunomodulatory and trophic 
capacity by secreting anti-inflammatory factors and 
growth factors [5], which might improve the 
inflammatory and catabolic aspects of OA. 
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Monosodium iodoacetate injection (MIA) to intra 
articular has been studied extensively as a model for 
OA in animals [6], [7] and is regarded as a suitable 
model and resembles a phenomenon observed in 
human OA [8]. 
Matrix metalloproteinase-1 is one of the 
protease enzymes that acts to degrade the 
components of the main cartilage matrix, such as 
collagen, aggrecan, link protein, and cartilage 
oligomer proteins [9], [10] while IL-4 and other 
cytokines are secreted in large amounts to counter the 
inflammatory response when Th2 dominates inflamed 
tissue because these immunomodulatory cytokines 
can reduce the production and activity of 
proinflammatory cytokines which are classified as 
inhibitors [11]. 
This study aims to prove the influence of 
Mesenchymal Stem Cell Wharton Jelly on decreasing 
MMP-1 levels and increasing IL-4 which is a specific 
target as a target component in cases of osteoarthritis 
in vivo. 
 
 
Material and Methods 
 
Animal and Experimental Design 
Male, white rats (Rattus novergicus) with a 
weight ranging from 200-250 grams as experimental 
animals placed in clean, disinfected and pathogen-
free cages and given standard food in the form of 
pellets and drinking in ad libitum. Trial animals 
adapted first for 1 week before treatment. Induction of 
osteoarthritis conducted with 300 g intra-articular 
injection of monosodium iodoacetate (MIA) (Sigma 
Aldric, USA) in 50 l of saline solution (0.9% NaCl) 
sterile (12) single into the right knee joint rats 
anaesthetized by intraperitoneal injection of xylazine 
10 mg/kg and ketamine 20 mg/kg uses insulin syringe 
with a needle (needle) 27G. 32 osteoarthritis male, 
white rats (three weeks after MIA induction) were 
divided into 2 treatment groups (n = 16): Control group 
and MSC-WJ group. MSC group-WJ is given 50 l 
MSC-WJ with a dose of 1 x 10
6
 cells into the right 
knee joint and a control group given 50 l complete 
medium after anaesthetized.  
Mesenchymal Stem Cell Wharton Jelly was 
obtained from the Indonesian Medical Education and 
Research Institute (IMERI) Faculty of Medicine, 
University of Indonesia. Based on the analysis of flow 
cytometry, MSC-WJ used for this therapy had CD73-
APC cell surface expression 99.8%, CD105-PerCP-
Cys5.5 95% and CD90-FITC 99.9%. Rats were 
sacrificed after 3 weeks of treatment. Serum and knee 
joint were taken and then analysed. 
 
Analysis of Flow Cytometry 
Mesenchymal Stem Cell Wharton Jelly was 
obtained from the Indonesian Medical Education and 
Research Institute (IMERI) Faculty of Medicine, 
University of Indonesia. Based on the analysis of flow 
cytometry, MSC-WJ used for this therapy had CD73-
APC cell surface expression 99.8%, CD105-PerCP-
Cys5.5 95% and CD90-FITC 99.9%. The photocell 
was taken use Nikon Ti-S microscope. Scale bar: 500 
μm. 
 
Histological Analysis 
The right knee joint from the two groups and 
the left knee joint (normal) was cut and fixed in 4% 
formalin for 1 weekend calcified with formic acid (5%) 
for 3 days. The specimen then underwent automatic 
network processing for 24 hours. The tissue planted in 
paraffin and cutting using a microtome with a 
thickness of 5 m. Ribbon cutting results were placed 
on the surface of warm water with a temperature of 
45°C to remove folds on the ribbon due to cutting. 
Every ribbon was stained with Hematoxylin and Eosin 
(H&E). 
 
Measurement of serum MMP-1 and IL-4 by 
ELISA 
Blood was taken from sinus periorbital and 
centrifuged at 3000 rpm for 15 minutes. The collected 
serum was stored at -80°C until measurement. Serum 
MMP-1 and IL-4 levels were measured by an ELISA 
kit (Bioassay Technology Laboratory, China). All 
samples are measured in duplicate. 
 
Examination of MMP-1 Levels (Work 
protocol based on rat MMP-1 ELISA Kit) 
Prepare all reagents, standard solutions and 
samples as instructed. Bring all reagents to room 
temperature before use. The assay is performed at 
room temperature. Determine the number of strips 
required for the assay. Insert the strips in the framers 
for use. The unused strips should be stored at 2-8°C. 
Add 50 µL standard well. Add 40 µL sample to sample 
wells and then add 10 µL anti-MMP-1 antibody to 
sample wells, then add 50 µL streptavidin-HRP to 
sample wells and standard wells (Not blank control 
well). Mix well. Cover the plate with a shaker. Incubate 
60 minutes at 37°C. Removed the sealer and wash 
the plate 5 times with wash buffer. Soak wells with at 
least 0,35 ml wash buffer for 30 seconds to minute for 
each wash. For automated washing, aspirate all wells 
and wash 5 times with wash buffer, overfilling wells 
with wash buffer. Blot the plate onto paper towels or 
other absorbent material. Add 50 µL substrate solution 
A to each well and then add 50 µL substrate solution 
B to each well. Incubate plate covered with a new 
sealer for 10 minutes at 37°C in the dark. Add 50 µL 
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stop solution to each well; the blue colour will change 
into yellow immediately. Determine the optical density 
(OD value) of each well immediately using a 
microplate reader set a 450 nm within 30 min after 
adding the stop solution.  
 
Examination of IL-4 Levels (Work protocol 
based on rat IL-4 ELISA Kit) 
Prepare all reagents, standard solutions and 
samples as instructed. Bring all reagents to room 
temperature before use. The assay is performed at 
room temperature. Determine the number of strips 
required for the assay. Insert the strips in the framers 
for use. The unused strips should be stored at 2-8°C. 
Add 50 µL standard well. Add 40 µL sample to sample 
wells and then add 10 µL anti-MMP-1 antibody to 
sample wells, then add 50 µL streptavidin-HRP to 
sample wells and standard wells (Not blank control 
well). Mix well. Cover the plate with a shaker. Incubate 
60 minutes at 37°C. Removed the sealer and wash 
the plate 5 times with wash buffer. Soak wells with at 
least 0,35 ml wash buffer for 30 seconds to minute for 
each wash. For automated washing, aspirate all wells 
and wash 5 times with wash buffer, overfilling wells 
with wash buffer. Blot the plate onto paper towels or 
other absorbent material. Add 50 µL substrate solution 
A to each well and then add 50 µL substrate solution 
B to each well. Incubate plate covered with a new 
sealer for 10 minutes at 37°C in the dark. Add 50 µL 
stop solution to each well; the blue colour will change 
into yellow immediately. Determine the optical density 
(OD value) of each well immediately using a 
microplate reader set a 450 nm within 30 min after 
adding the stop solution.  
 
Research Ethics 
This study was already passed the ethics 
clearance and has been approved by the Ethics 
Committee of the Faculty of Medicine, Andalas 
University, Padang with registration number: 
549/KEP/FK/2017. 
 
Statistical analysis 
Data is presented in mean and elementary 
forms. The statistical analysis used is SPSS 18.0. The 
statistical test used is an independent t-test. The value 
of p < 0.05 was said to be statistically significant. 
 
 
Result 
 
A study of 32 osteoarthritis rats induced with 
monosodium iodoacetate (MIA) for 3 weeks was 
carried out. OA rats were divided into 2 groups, 
namely the control group and the group treated with 
MSC-WJ (Figure 1). Three weeks after MSC therapy, 
termination was done at the expense of experimental 
animals. Then a histopathological examination of 
mouse right knee (OA) was carried out. Examination 
of the levels of MMP-1 and IL-4 was carried out in the 
serum of rats by ELISA. 
 
Figure 1: Data on Characteristics of Mesenchymal Stem Cells 
Wharton Jelly. (A) Cells MSC-WJ reach confluence. Scale bar: 500 
µM. Photographs of cells taken using a Nikon Ti-S microscope; (B) 
Data flow cytometry. Forward scatter (FCS) plot&side scatter (SSC) 
plot. Population gated events (P1): 20,000; (C) Cell surface markers 
expression: CD73-APC 99.8% and CD105- PerCP-Cy5.5 95%; (D) 
Cell surface markers expression: CD90-FITC 99.9% and Lin (-) - PE 
0.4% 
 
Histopathology examination 
After the bone portion of the rat's knee is 
obtained preserved with formalin buffer, 
Histopathological examination was carried out using 
Hematoxylin-Eosin staining; the results are shown in 
figure 2. The results we can see in tissue reactions 
are changes in the thickness of cartilage and the 
number of chondrocytes. 
 
Figure 2: Microscopic joint tissue of experimental animals, showed 
joint fragility (Kh), bone tissue (Os) in normal rats, osteoarthritis 
(OA), and OA + MSC-WJ. Objective hematoxylin-eosin 
100 µm 
 
Os  
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Histopathological results show joint tissue 
with the surface consisting of cartilage with 
chondrocyte cells. In the OA group, there were areas 
with a thickness of cartilage that was thinner than 
normal animals and OA animals injected by MSC-WJ 
(Figure 2). 
In addition to changes in the thickness of the 
cartilage, histopathological results also showed an 
increase in chondrocyte cell density in the OA mouse 
group compared to normal rats. In the OA group, of 
rats given MSC-WJ, the density of chondrocyte was 
close to the mean of normal rats. 
 
ELISA examination 
The blood obtained from the centrifuged 
animal is then obtained serum. Serum before analysis 
was stored in a refrigerator temperature of -80°C. The 
serum obtained was analysed for MMP-1 and IL-4 
levels carried out in the Biomedical laboratory FK 
Unand. 
The measurement of MMP-1 and IL-4 levels 
were carried out in normal rat, and the mean levels of 
MMP-1 and IL-4 were 1.62 ng/ml and 34.27 ng/ml. 
Based on the results of the normality test the data 
showed that the two research variables namely MMP-
1 and IL-4 were normally distributed (p > 0.05). Thus, 
furthermore, parametric tests (free t-test) can be 
carried out. 
 
Effect of MSC-WJ on serum MMP-1 levels 
in OA rats treated with MSC-WJ 
The measurement of MMP-1 levels by ELISA 
method showed that the serum MMP-1 levels of OA 
rat treated with MSC-WJ were higher than those not 
treated which can be seen in Figure 3. 
 
Figure 3: Boxplot graph of rat serum MMP-1 levels 
 
The difference in MMP-1 levels between 
serum of rats treated with MSC-WJ and control can be 
seen in Table 1. 
Table 1: Differences in mean levels of MMP-1 by group 
Groups MMP-1 levels (ng/ml) 
(Mean ± SD) 
P value 
Control 2.63 ± 0.55 0.001 
MSC-WJ 3.96 ± 0.81  
 
Table 1 showed that there are differences in 
MMP-1 levels based on treatment. Increased levels of 
MMP-1 in the group treated with MSC-WJ from the 
control group. There were significant differences, 
between MSC-WJ with control (p < 0.05).  
 
Effect of MSC-WJ on IL-4 levels in serum 
of OA rats 
The results of measurement of IL-4 levels by 
ELISA method showed that the serum IL-4 levels of 
OA rats treated with MSC-WJ were higher than those 
not treated with bivariate tests which can be seen in 
Figure 4. 
 
Figure 4: Boxplot graph of rat serum IL-4 levels 
 
The difference in IL-4 levels between serum 
of rats treated with MSC-WJ and control can be seen 
in Table 2. 
Table 2 Mean differences in IL-4 levels by group 
Groups IL-4 Levels (ng/l) 
(Mean ± SD) 
P value 
Control 43.90 ± 4.99 0.027 
MSC-WJ 47.95 ± 4.88  
 
Table 2 showed that there are differences in 
IL-4 levels based on treatment. Increased IL-4 levels 
in the group treated with MSC-WJ from the control 
group. There were significant differences, between 
MSC-WJ with control (p < 0.05).  
 
 
Discussion 
 
The results showed that MIA induction in rats 
with a single dose of 300 g after 3 weeks showed the 
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reduced thickness of cartilage. The results of this 
study are also the same as those conducted by 
Janusz et al., (2001) regarding the effect of MIA on rat 
cartilage, wherein the study there was also reduced of 
cartilage in the surrounding area after one week of 
MIA induction [13]. 
This reduced cartilage occurs due to the loss 
of proteoglycans that build up the matrix. Also, the 
results of this study also showed a form of reactive 
chondroblast cell proliferation, so that cell densities 
were higher than those of OA rat cartilage that was 
not treated with MSC-WJ. 
The results of the serum analysis using the 
ELISA method showed a tendency to increase serum 
MMP-1 and IL-4 levels compared to the serum of non-
induced (normal) rat. This increase is due to 
chondrocyte cells and immune cells stimulated by 
inflammatory cytokines (IL- and TNF-) whose levels 
increase when inflammation occurs due to MIA 
induction. 
Increased matrix-degrading enzymes and 
anti-inflammatory cytokines after MIA induction 
showed that rats experienced osteoarthritis. Induction 
of MSC-WJ in OA rat for 3 weeks showed a thickness 
of joint cartilage close to the thickness of normal 
cartilage and showed lower cell density closer to 
normal compared to OA rat. This shows the 
appearance of tissue repair in osteoarthritis by MSC-
WJ. 
 
Matrix metalloproteinase-1 (MMP-1) 
Matrix metalloproteinase-1 is one of the 
protease enzymes that act to degrade the 
components of the main cartilage matrix, such as 
collagen, aggrecan, link protein, and cartilage 
oligomer proteins [14], [15]. This enzyme also 
functions to increase the proliferation and migration of 
MSCs [16]. MMP-1 increases production in synovial 
membranes, synovial fluid, and human cartilage that 
undergo OA [17], also in the serum of OA rat 
significantly [2]. The release of MMP-1 protein by 
human articular chondrocyte is stimulated by IL-1β 
[18]. 
This study showed that the serum MMP-1 
levels of OA rat treated with MSC-WJ were higher 
than those not treated. Research by Saulnier et al., 
(2015) showed that the administration of MSC in 
rabbits OA had was not effective in reducing the 
expression of MMP-1 after 2 weeks of injection with 
MSC, but effectively reduced MMP-1 expression after 
8 weeks of injection [19]. 
The results of this study indicate that MSC-
WJ therapy has not been effective in reducing MMP-1 
levels within 3 weeks after injection. Possibly in this 
period, MSC-WJ was still synthesising and releasing 
MMP-1 which is needed for the apoptosis of 
chondrocyte and synovial cells [20], the process of 
MSC migration and proliferation [16] and 
differentiation. Ho et al., (2009) showed that MMP-1 
plays an important role in the MSC migration function, 
which operates through MMP1-PAR1 axis signalling 
[21]. According to Voronkina et al., (2017) that the 
involvement of MMP-1 is in the process of MSC 
differentiation, namely the increase in MMP-1 activity 
during the differentiation process [22]. 
The high levels of MMP-1 in OA mice treated 
with MSC-WJ were compared with OA mice that were 
not treated because in this period MSC expressed 
MMP-1 constitutively [23]. It is possible that MSC-WJ 
requires MMP-1 in repairing cell damage because it 
involves the process of apoptosis, migration and MSC 
differentiation and proliferation. 
 
Interleukin-4 (IL-4) 
Interleukin-4 (IL-4) is an anti-inflammatory 
cytokine that plays a role in stimulating the 
proliferation of B cells and T cells and encourages 
differentiation of CD4 + T cells into Th2. IL-4 also 
plays a key role in regulating humoral and adaptive 
immunity. IL-4 and other cytokines are secreted in 
large amounts to counter the inflammatory response 
when Th2 dominates inflamed tissue. Because these 
immunomodulatory cytokines can reduce the 
production and activity of proinflammatory cytokines 
which are classified as inhibitors [11]. 
Research by Hui et al., (2005) found that IL-4 
was reported to play a role in the regulation of 
ADAMTS-4 in chondrocyte, although the exact 
mechanism has not been explained [24]. The proteins 
secreted by rat MSC and humans are chemokines, 
cytokines, growth factors and protease inhibitors [25], 
including IL-4, IL-10, and IL-13 which are anti-
inflammatory cytokines [26]. 
In this study, it was found that IL-4 levels were 
higher in the serum of OA rat treated with MSC-WJ 
compared with those not treated. The same thing was 
found in the study of Kay et al., (2017) which showed 
that IL-4 expression was higher in arthritis rats given 
MSC compared to those not given [27]. Whereas Yan 
et al., (2017) research found that serum IL-4 levels of 
arthritis rats treated with MSC were compared with 
serum of non-treated arthritis rats, but the difference 
was not significant [28]. Chai et al., (2016) also found 
the same thing that UC-MSC can increase IL-4 in liver 
fibrosis both in vitro and in vivo [29]. 
Increased levels of IL-4 in the serum of OA 
mice show that MSC-WJ can increase the 
immunosuppressive activity of Th2 cells. MSC 
increases anti-inflammatory cytokines such as IL-4 
which have anti-inflammatory effects through inhibition 
of the NF-κB cascade, which contributes to the 
regulation of proinflammatory cytokines [30]. MSC 
plays an important role in cartilage repair through 
direct differentiation into chondrocyte and paracrine 
effects [31], [32]. 
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Information about the increase in expression 
in the form of serum IL-4 proteins in this study is 
important for the development of MSC-WJ as a 
therapy for osteoarthritis. The development of MSC-
WJ as a therapy for osteoarthritis is quite promising. 
Differences in IL-4 levels between serum of rats 
treated and those not treated with MSC-WJ proved 
that MSC-WJ had a therapeutic effect. Thus, the 
information obtained encourages further studies of 
MSC-WJ as a treatment for OA. 
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